Value based healthcare and Health Technology Assessment for emerging market countries: joint efforts to overcome barriers.
Maximillian OtteHans Peter DaubenJeong Hoon AhnIñaki Gutierrez IbarluzeaMichael DrummondSteven SimoensZoltán KalóDong-Churl SuhPublished in: Expert review of pharmacoeconomics & outcomes research (2024)
RWE emerged as important in understanding biosimilar value recognition and decision-making processes, with insights into its applications and challenges. Recommendations were provided for utilizing Multi-Criteria Decision Analysis (MCDA) in pharmaceutical procurement, particularly for off-patent medicines, underscoring the importance of comprehensive evaluation frameworks and adherence to value-based principles. Overall findings suggest avenues for collaboration between industry, academia, and public agencies to address implementation barriers and promote equitable, efficient, and high-quality healthcare systems in emerging markets through public-private partnerships, joint capacity building and training initiatives, and knowledge transfers.